Nephrotoxic Burden and Consequences Associated with Drug Induced AKI (D-AKI)
|
|
- Edwin Bates
- 5 years ago
- Views:
Transcription
1 Nephrotoxic Burden and Consequences Associated with Drug Induced AKI (D-AKI) Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP Associate Professor, University of Pittsburgh Critical Care Medication Safety Pharmacist, UPMC
2 OBJECTIVES Support the importance of nephrotoxic burden as a risk for AKI. Explain the negative consequences attributable to D-AKI. Disclosures: None
3 PREVALENCE OF DRUG ASSOCIATED ACUTE KIDNEY INJURY (D-AKI) IN THE ICU 5,143 patients in 20 ICUs 20% (74/355) associated with drugs ICUs at 5 hospitals 3 rd -5 th 25% (157/618) associated with drugs 26,269 critically ill patients in 54 hospitals in 23 countries 19% (328/1726) associated with drugs Brivet FG et al. Crit Care Med 1996;24:192; Mehta RL et al. Kid International 2004;66: ; Uchino S et al. JAMA 2005;294:
4 RISK FACTORS FOR AKI/D-AKI Description Susceptibilities Exposures Drug-specific Exposure Risk Factors for Critically Ill Age, black race, female,history of diabetes, history of hypertension, previous AKI episode, elevated baseline serum creatinine Nephtoroxin administration, trauma, burn, circulatory shock, sepsis, high risk surgery, hypotension, fluid overload Nephrotoxin treatment duration, cumulative dose, total daily dose, pharmacokinetic and pharmacodynamic drug interactions, nephrotoxic burden Kane-Gill SL, Goldstein SL. Crit Care Clin 2015;31:675 Cotner SE et al. AAC 2017;61:e00871 Cartin-Ceba R et al. Crit Care Res Pract 2012; article ID Ostermann M et al. Crit Care Med 2018: ahead of print Concomitant nephrotoxin administration was an independent predictor of AKI 53% greater odds of developing AKI for every nephrotoxic drug received (OR 1.53; CI ) Significant association between cumulative number of exposures and risk of AKI (p = 0.02) but no association between the each type of exposure and AKI (p = 0.22)
5 NEPHROTOXIC BURDEN IS A CONCERN
6 ADVANCE OUR THINKING BEYOND SINGLE NEPHROTOXINS: DRUG COMBINATIONS Evidence for drug class combinations associated with AKI Completed a formal GRADE process for quality of evidence assessment 76 unique drug combinations 74% very low quality of evidence (D) 16% low quality of evidence (C) 10% moderate quality of evidence (B) 0% high quality of evidence (A) Rivosecchi RM et al. Ann Pharmacother 2016;50:
7 DRUG COMBINATIONS: MODERATE QUALITY OF EVIDENCE Drug Class 1 Drug Class II Mechanism NSAIDs Diuretic pharmacodynamic effect with a decrease in prostaglandin synthesis by NSAIDs causing afferent vasoconstriction and a decrease in effective blood volume by diuretics NSAIDs Diuretic plus reninangiotensin aldosterone system triple whammy cumulative pharmacodynamic effect of each drug - exacerbated by the efferent arteriolar vasodilation caused by the RAAS Statins Macrolide increased serum statin concentrations as a result of inhibition of the cytochrome 450 (CYP450) enzyme system by macrolides Calcium channel blockers Statins Piperacillin/tazobactam Clarithromycin Calcium channel blockers Vancomycin CYP3A4 inhibition of clarithromycin, leading to elevated concentrations of calcium channel blockers leads to global hypotension, affecting the kidney results in ischemic renal injury resulting in AKI drug-drug interaction between certain calcium channel blockers inhibiting CYP3A4 metabolism of statins metabolized through this pathway decreased vancomycin clearance caused by piperacillin/tazobactam potentially leading to a greater degree of vancomycin exposure Rivosecchi RM et al. Ann Pharmacother 2016;50:
8 Vancomycin- AKI VANCOMYCIN AND PIPERACILLIN/TAZOBACTAM ASSOCIATED AKI Renal tubular ischemia following oxidative effects on proximal renal tubule cells- reports of ATN> AIN Relative risk 2.45 (95% CI ) compared to nonglycopeptide antibiotics with moderate level of evidence Piperacillin/tazobactam- AKI Similar rates of AKI for piperacillin/tazobactam compared to ampicillin/sulbactam was 9.5% vs. 8.9%, respectively. Pooled percentages indicate odds of AKI for piperacillin/tazobactam monotherapy > vancomycin monotherapy (Luther 2018) Acute interstitial nephritis (AIN)- characterized by inflammatory infiltrate localizing in renal interstitium Ray AS et al. CJASN 2016;11:2132 Bamgbola O et al. Ther Adv Endocriol Metabl 2016;7:136 D Hoore et al. J Nephrol 2015;28:709 Panwar et al. Am J Med Sci 2013;345:396
9 META-ANALYSES SUMMARY: VANCOMYCIN PLUS PIPERACILLIN/TAZOBACTAM Population Hammond et al # of studies OR (95% CI) Luther et al (adults) # of studies OR (95% CI) Giuliano CA et al (adults) # of studies OR (95% CI) All studies (2-4.8) ( ) Adults ( ) Children 3 5.3( ) V + β lactam** 6 3.6( ) 4 3.0( ) V + Cefepime or carbapenem 4 7.1( ) ( ) V alone ** 3 3.2( ) 18 (5) 3.4 ( ) ( ) PT alone ( ) Good Quality 8 2.4( ) 5 3.0( ) Fair/Poor ( ) Critically ill 4 3.8( ) ( ) Non-ICU 7 2.4( )
10 WHY? Piperacillin/tazobactam Similar rate of AKI for piperacillin/tazobactam compared to ampicillin/sulbactam was 9.5% vs 8.9%, respectively (Rutter 2017); however addition of vancomycin was 18% vs 10% for the combinations. Longer renal recovery rate than other beta-lactams (Jensen 2012) Additive effect of acute interstitial nephritis from piperacillin/tazobactam plus direct cellular necrosis from vancomycin (Hammond 2017) Contrary opinion Longer renal recovery rate compared other beta-lactams but when piperacillin/tazobactam is discontinued SCr resolves (Jensen 2012) pip/tazo competitively inhibits organic anion transport system causing psuedo-nephrotoxicity (Farkas 2016) Need to Answer- Severity/Dialysis? Dialysis rate in piperacillin/tazobactam 19% and comparator groups 38% (p = 0.277) (Hammond 2016)
11 CONSEQUENCES OF D-AKI
12 D-AKI CONSEQUENCES PEDIATRIC, NON-ICU PATIENTS Variable Baseline egfr (ml/min/1.73m2) egfr at 6 months (ml/min/1.73m2) Up/C ratio at 6 months, mg/mg AKI due to Nephrotoxin (n=77) No AKI P Value Hypertension 37.7% sign of CKD < % of patients with drug associated AKI have evidence (reduced egfr, hyperfiltration, proteinuria, or hypertension) of residual kidney damage Menon S et al. J Pediatr 2014;165:522
13 D-AKI CONSEQUENCES 60% 50% 40% 30% Acute Tubular Necrosis (ATN) Nephrotoxicity 20% 10% ATN + Nephrotoxicity 0% In-Hospital Mortality In-Hospital Mortality and/or Dialysis Dependence Other Etiologies Similar, slightly better, mortality rates and/or dialysis dependence compare to AKI of other etiologies Mehta RL et al. Kid Int 2004;66:1613
14 TRANSITIONING FROM ACUTE KIDNEY INJURY TO CHRONIC KIDNEY DISEASE Patients with AKI have a substantial risk of progressing to CKD About 30% of patients who have AKI progress to CKD Dialysis dependence for AKI survivors is 40% Chawla LS et al. Nat Rev Nephrol 2017;13:241. AKI- acute kidney injury AKD- acute kidney disease CKD- chronic kidney disease
15 COLISTIN-AKI TO CKD Up to 40% of patients receiving Purpose Predictors of CKD in survivors of multi-drug resistant infections with colistin-associated AKI Methods Retrospective cohort of pts. with colistin-associated AKI (n=72) compared to controls (n=58), matched by age, sex, diabetes, vancomycin use and baseline kidney fxn Outcome caspase-mediated apoptosis, inducible nitric oxide synthesase (inos), caspase 1, and calpain 1 are involved in the pathogenesis of colistin-associated nephropathy Development of CKD after 6 months of follow-up Ozkan G et al. AAC 2013;57:3463 Meraz-Munoz A et al. J Crit Care 2017;44:244 Results CKD in 75% of colistin group compared to 27% controls; Predictors- colistin exposure (OR 8.9) and age (OR 1.04)
16 COST OF AKI Admission to 1-yr for Hospitalized Adults Total Cost Incremenatal Cose Total Costs Incremental Costs Admissions for Hospitalized Adults from Recovered Not Recovered Collister D et al. Clin J Am Soc Nephrol 2017: 12:1733 Recovery or 90 days to 1-year
17 MONITORING BEYOND INITIAL ONSET OF D-AKI IS NEEDED TO PREVENT CHRONIC COMPLICATIONS
18 FOLLOW UP IS POOR Guidelines recommend follow up within 3 months of acute kidney injury episode Medicare Population High Risk for Progression to CKD 13% saw a nephrologist 75% saw a primary care physician 12% no follow up 25% saw a nephrologist 75% not with a nephrologist Silver SA, Siew ED. Adv Chronic Kidney Dis. 2017;24(4): Saran R, et al. Am J Kidney Dis. 2016;67(3 Suppl 1):Svii, S1-305.
19 FOLLOW UP IS POOR Guidelines recommend follow up within 3 months of acute kidney injury episode Medicare Population High Risk for Progression to CKD 13% saw a nephrologist 75% saw a primary care physician 12% no follow up 25% saw a nephrologist 75% not with a nephrologist Only 60% had a creatinine checked Silver SA, Siew ED. Adv Chronic Kidney Dis. 2017;24(4): Saran R, et al. Am J Kidney Dis. 2016;67(3 Suppl 1):Svii, S1-305.
20 BUT FOLLOW UP CAN IMPROVE OUTCOMES! All-cause mortality was lower in patients with early nephrology follow-up compared with those without (8.4 compared with 10.6 per 100-patient years, hazard ratio 0.76 (95% CI: )) Harel Z et al. Kidney Int2013;83:901
21 PUBLIC KNOWLEDGE 1 in 2 people know their kidneys make urine 1 in 8 thought kidneys processed medications Most drugs and or their metabolites are eliminated by the kidney at least 75% 2 in 10 are aware that they experienced an episode of AKI in the hospital This is a public concern and needs to be improved. Further problem: 68% had not heard of AKI
22 BEGINS WITH HEALTH LITERACY ABOUT MEDICATIONS Patients with low health literacy have difficulty taking prescription medications Medication errors are linked to a patient's understanding of the indication, dosage schedule, proper administration, and potential adverse effects 2 in 10 patients take a drug like ibuprofen after an acute kidney injury episode Lipworth L, et al. BMC Nephrol. 2016;17(1):189. AHRQ PSNet and Wolf MS et al. Patient Educ Couns 2007;67:293.
23 MEDICATION MANAGEMENT APPROACH FOR AKD
24 FOCUS AT HOSPITAL DISCHARGE AND BEYOND Discussion with patient at hospital discharge about AKI and medications Medications Which to avoid Consider appropriate dosing Verbal discussion and written information Encourage consultation with a pharmacist about medications after their hospital stay Encourage follow with a physician and conversation about AKI after their hospital stay Kane-Gill SL et al. Hosp. Pharm 2017;52:663 Ostermann M et al. Br J Clin Pharmacol 2018;84:396
25 PROVIDE A MOBILE APPLICATION FOR PATIENT USE: MYKIDNEY Allows patient to enter laboratory values From hospital and over time Allows patient to enter medications Provides caution signals for medications Provides some education about AKI Can be used as a tool to communicate with the physician during a follow up visit
26 Silver SA et al. Can J Kidney Health Dis 2015;2:36 WALLET CARD
27 SUMMARY Advanced thinking requires consideration of nephrotoxic burden as a cause of AKI Piperacillin/tazobactam results in increased serum creatinine however the contribution to AKI in combination with vancomycin is still unclear Similar, slightly better, mortality rates and/or dialysis dependence for D-AKI compared to AKI from other etiologies AKI transition to CKD concerning so post-aki monitoring, education and medication management is important.
Best Practices in Renal Dosing
Best Practices in Renal Dosing Bruce A. Mueller, PharmD Professor of Clinical Pharmacy University of Michigan College of Pharmacy Ann Arbor, MI LEARNING OBJECTIVES At the end of this lecture, the learner
More informationBiomarkers for the Prevention of Drug Induced AKI (D-AKI)
Biomarkers for the Prevention of Drug Induced AKI (D-AKI) Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP Associate Professor, University of Pittsburgh Critical Care Medication Safety Pharmacist, UPMC OBJECTIVE
More informationAcute Kidney Injury for the General Surgeon
Acute Kidney Injury for the General Surgeon UCSF Postgraduate Course in General Surgery Maui, HI March 20, 2011 Epidemiology & Definition Pathophysiology Clinical Studies Management Summary Hobart W. Harris,
More informationAcute kidney injury definition, causes and pathophysiology. Financial Disclosure. Some History Trivia. Key Points. What is AKI
Acute kidney injury definition, causes and pathophysiology Financial Disclosure Current support: Center for Sepsis and Critical Illness Award P50 GM-111152 from the National Institute of General Medical
More informationCLINICAL DECISION SUPPORT FOR ME/ADE PREVENTION
CLINICAL DECISION SUPPORT FOR ME/ADE PREVENTION Sandra Kane-Gill, PharmD, MSc, FCCP, FCCM Associate Professor of Pharmacy, Critical Care Medicine and the Clinical Translational Science Institute, University
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More informationThe Link Between Acute and Chronic Kidney Disease. John Arthur, MD, PhD
The Link Between Acute and Chronic Kidney Disease John Arthur, MD, PhD Conventional Dogma Conventional dogma was that if a patient survived and recovered from AKI, he was unlikely to have long-term sequela.
More informationCystatin C: A New Approach to Improve Medication Dosing
Cystatin C: A New Approach to Improve Medication Dosing Erin Frazee Barreto, PharmD, MSc, FCCM Assistant Professor of Pharmacy and Medicine Kern Scholar, Center for the Science of Health Care Delivery
More informationAugmented Renal Clearance: Let s Get the Discussion Flowing
Augmented Renal Clearance: Let s Get the Discussion Flowing Terry Makhoul, PharmD PGY-2 Emergency Medicine Pharmacy Resident University of Rochester Medical Center Strong Memorial Hospital Disclosures
More informationCaring for the AKI Survivor: What is Required?
Caring for the AKI Survivor: What is Required? Ron Wald, MDCM MPH FRCPC Division of Nephrology St. Michael s Hospital and University of Toronto February 28, 2019 A patient in your ICU 65M with DM, HTN,
More informationFaculty/Presenter Disclosure
CSI for CKD Unravelling the myths surrounding chronic kidney disease Practical Evidence for Informed Practice Oct 21 2016 Dr. Scott Klarenbach University of Alberta Slide 1: Option B (Presenter with NO
More informationContrast-Induced Nephropathy: Evidenced Based Prevention
Contrast-Induced Nephropathy: Evidenced Based Prevention Michael J Cowley, MD, FSCAI Nothing to disclose Contrast-Induced Nephropathy (CIN) Definitions New onset or worsening of renal function after contrast
More informationSAFETY IN THE CATH LAB How to Minimise Contrast Toxicity
SAFETY IN THE CATH LAB How to Minimise Contrast Toxicity Dr. Vijay Kunadian MBBS, MD, MRCP Senior Lecturer and Consultant Interventional Cardiologist Institute of Cellular Medicine, Faculty of Medical
More informationUne promenade dans l'épidémiologie de l'insuffisance rénale aiguë en quatre étapes
Une promenade dans l'épidémiologie de l'insuffisance rénale aiguë en quatre étapes Fernando Liaño Hospital Universitario Ramón y Cajal Madrid, España Genéve, 14-12-2012 Une promenade dans l'épidémiologie
More informationThe 2012 KDIGO guidelines on Acute Kidney Injury-
The 2012 KDIGO guidelines on Acute Kidney Injury- Is there a need for an update and have the guidelines improved AKI prognosis? Norbert Lameire, MD,PhD Em prof of Medicine and Nephrology University Hospital
More informationSouthern Derbyshire Shared Care Pathology Guidelines. AKI guidelines for primary care
Southern Derbyshire Shared Care Pathology Guidelines AKI guidelines for primary care Contents: Flow Diagram: Recommended response time to AKI warning stage test results for adults in primary care 2 Table
More informationChapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury In 2015, 4.3% of Medicare fee-for-service beneficiaries experienced a hospitalization complicated by Acute Kidney Injury (AKI); this appears to have plateaued since 2011
More informationLearning Objectives. How big is the problem? ACUTE KIDNEY INJURY
ACUTE KIDNEY INJURY Karen Innocent, DNP, RN, CRNP, ANP-BC, CMSRN Executive Director, Continuing Education Wolters Kluwer Health, Inc May 2016 Orlando FL Learning Objectives Identify the risk factors and
More informationRCP : Regional Update in Medicine Acute Kidney Injury : A Renal Problem?
RCP : Regional Update in Medicine Acute Kidney Injury : A Renal Problem? Lui G Forni : Consultant Intensivist & Nephrologist Faculty of Health Sciences : University of Surrey Disclosures Research Funding
More informationChapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury Introduction In recent years, acute kidney injury (AKI) has gained increasing recognition as a major risk factor for the development of chronic kidney disease (CKD). The
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationNovel Biomarkers in Critically Ill Patients and the Emergency Room
Novel Biomarkers in Critically Ill Patients and the Emergency Room Jay L. Koyner MD Section of Nephrology University of Chicago Research Funding: NIDDK, Abbvie, Astute, Argutus Outline Background / Pitfalls
More informationWEEK. MPharm Programme. Acute Kidney Injury. Alan M. Green MPHM13: Acute Kidney Injury. Slide 1 of 47
MPharm Programme Acute Kidney Injury Alan M. Green 2017 Slide 1 of 47 Overview Renal Function What is it? Why does it matter? What causes it? Who is at risk? What can we (Pharmacists) do? How do you recognise
More informationENDPOINTS FOR AKI STUDIES
ENDPOINTS FOR AKI STUDIES Raymond Vanholder, University Hospital, Ghent, Belgium SUMMARY! AKI as an endpoint! Endpoints for studies in AKI 2 AKI AS AN ENDPOINT BEFORE RIFLE THE LIST OF DEFINITIONS WAS
More informationDoncaster & Bassetlaw. AKI guidelines for primary care
Doncaster & Bassetlaw AKI guidelines for primary care Contents: FLOW DIAGRAM: MANAGEMENT OF PATIENTS WITH AKI DETECTED IN PRIMARY CARE... 2 FLOW DIAGRAM: MANAGEMENT OF HYPERKALAEMIA.... 3 FLOW DIAGRAM:
More informationAcute Kidney Injury in Trauma. David Lee Skinner MBChB FCS(SA) Trauma Unit Inkosi Albert Luthuli Central Hospital KwaZulu Natal South Africa
Acute Kidney Injury in Trauma David Lee Skinner MBChB FCS(SA) Trauma Unit Inkosi Albert Luthuli Central Hospital KwaZulu Natal South Africa Acute Kidney Injury Acute Renal Failure RIFLE & AKIN RIFLE criteria
More informationLas dos caras de la cretinina sérica The two sides of serum creatinine
Las dos caras de la cretinina sérica The two sides of serum creatinine ASOCIACION COSTARRICENSE DE MEDICINA INTERNA San José, Costa Rica June 2017 Kianoush B. Kashani, MD, MSc, FASN, FCCP 2013 MFMER 3322132-1
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationAutomated e-alerts & Integrated Clinical Decision Support in AKI
Automated e-alerts & Integrated Clinical Decision Support in AKI Sean M Bagshaw, MD, MSc Department of Critical Care Medicine, University of Alberta Canada Critical Care Forum, Toronto, Canada November
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationAdding Insult to Injury. Marlies Ostermann Consultant in Nephrology & Critical Care Guy s & St Thomas Hospital, London
Acute Kidney Injury Adding Insult to Injury Marlies Ostermann Consultant in Nephrology & Critical Care Guy s & St Thomas Hospital, London Content 1. Brief review of AKI and its impact 2. Comments on the
More informationProviding Home Infusion for the Patient with Compromised Renal Function
Providing Home Infusion for the Patient with Compromised Renal Function Carol J. Rollins, MS, PharmD, BCNSP Assistant Director, Clinical Pharmacy Services University Medical Center, Tucson, Arizona Top
More informationConflict of Interest. Providing Home Infusion for the Patient with Compromised Renal Function. Top 5 Things to Know for CE: 3/31/10
Providing Home Infusion for the Patient with Compromised Renal Function Carol J. Rollins, MS, PharmD, BCNSP Assistant Director, Clinical Pharmacy Services University Medical Center, Tucson, Arizona Top
More informationHow and why to measure renal function in patients with liver disease?
ow and why to measure renal function in patients with liver disease? P. Angeli, Dept. of Medicine, Unit of Internal Medicine and epatology (), University of Padova (Italy) pangeli@unipd.it 10th Paris epatology
More informationHeart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA
Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to
More informationRenal Transporters- pathophysiology of drug - induced renal disorders. Lisa Harris, Pharmacist, John Hunter Hospital, Newcastle, 2015 November
Renal Transporters- pathophysiology of drug - induced renal disorders Lisa Harris, Pharmacist, John Hunter Hospital, Newcastle, 2015 November Renal Failure Up to 25% of acute renal failure is drug induced
More informationSection Questions Answers
Section Questions Answers Guide to CKD Screening and Evaluation -Alec Otteman, MD Delaying Progression - Paul Drawz, MD, MHS, MS 1. Modifiable risk factors for CKD include: a. Diabetes b. Hypertension
More informationTHE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D.
THE KIDNEY IN HYPOTENSIVE STATES Benita S. Padilla, M.D. Objectives To discuss what happens when the kidney encounters low perfusion To discuss new developments and clinical application points in two scenarios
More informationChronic Kidney Disease for the Primary Care Physician in What do the Kidneys do? CKD in the US
1:25-2:25pm Managing Chronic Kidney Disease in 2019 SPEAKERS Adriana Dejman, MD Chronic Kidney Disease for the Primary Care Physician in 2019 Adriana Dejman, MD Assistant Professor of Clinical Medicine
More informationMinimizing the Renal Toxicity of Iodinated Contrast
Minimizing the Renal Toxicity of Iodinated Contrast Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Chief Academic and Scientific Officer St. John Providence Health System Detroit, MI USA Outline
More informationNarender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,
More informationAcute Kidney Injury in the ED
+ Acute Kidney Injury in the ED + Dr Eric Clark, MD FRCPC University of Ottawa Canada Canadian Association of Emergency Physicians + Outline 1. Diagnostic challenges 2. ED treatment 3. Contrast induced
More informationClinical Significance of ARF. Hospital Acquired Renal Insufficiency. Case - Acute Renal Failure. Hospital Acquired Renal Insufficiency
Case - Acute Renal Failure 73 yo diabetic F w hx of mild HBP but normal renal function develops infection of R foot. Over 1 week fever, chills, inflammation swelling of her R foot and leg. She takes Motrin
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationRecognizing and Treating Patients with the Cardio-Renal Syndrome
Recognizing and Treating Patients with the Cardio-Renal Syndrome Joachim H. Ix, MD, MAS, FASN Professor of Medicine Chief; Division of Nephrology-Hypertension University of California San Diego 1 Conflicts
More informationDiabetes and the Elderly: Medication Considerations When Determining Benefits and Risks
Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks Gretchen M. Ray, PharmD, PhC, BCACP, CDE Associate Professor UNM College of Pharmacy September 7 th, 2018 DISCLOSURES
More informationIdentifying and Managing Chronic Kidney Disease: A Practical Approach
Identifying and Managing Chronic Kidney Disease: A Practical Approach S. Neil Finkle, MD, FRCPC Associate Professor Division of Nephrology, Department of Medicine, Dalhousie University Program Director,
More informationA08 Using Kidney Biomarkers for AKI 2: Differential Diagnosis, Interventions and Prognosis
A08 Using Kidney Biomarkers for AKI 2: Differential Diagnosis, Interventions and Prognosis Kent Doi, MD, PhD Emergency and Critical Care Medicine, The Univ of Tokyo, Japan Using kidney biomarkers: Key
More informationCase - Acute Renal Failure
Case - Acute Renal Failure 73 yo diabetic F w hx of mild HBP but normal renal function develops infection of R foot. Over 1 week fever, chills, inflammation swelling of her R foot and leg. She takes Motrin
More informationCOMPLETE INHIBITION OF RENAL RESERVE IN CHRONIC RENAL FAILURE BY A COMBINATION OF ACEI AND ARB
COMPLETE INHIBITION OF RENAL RESERVE IN CHRONIC RENAL FAILURE BY A COMBINATION OF ACEI AND ARB CG Musso ¹, J Reynaldi¹, N Imperiali ¹, L Algranati ¹, DG Oreopoulos ² Nephrology Department Hospital Italiano
More informationAcute Kidney Injury (AKI)
(Last Updated: 08/22/2018) Created by: Socco, Samantha Acute Kidney Injury (AKI) Thambi, M. (2017). Acute Kidney Injury. Lecture presented at PHAR 503 Lecture in UIC College of Pharmacy, Chicago. AKI This
More informationSeverity and Outcome of Acute Kidney Injury According to Rifle Criteria in the Intensive Care Unit
BANTAO Journal 2010; 8 (1): 35-39 BJ BANTAO Journal Original Article Severity and Outcome of Acute Kidney Injury According to Rifle Criteria in the Intensive Care Unit Albana Gjyzari 1, Elizana Petrela
More informationGeneral introduction of nephrology. Xiaoqiang Ding M.D., Ph.D. Department of nephrology Zhongshan Hospital, Fudan University
General introduction of nephrology Xiaoqiang Ding M.D., Ph.D. Department of nephrology Zhongshan Hospital, Fudan University Terminology Kidney,renal Nephrology Scope of nephrology Kidney diseases and
More informationOptimal Use of Iodinated Contrast Media In Oncology Patients. Focus on CI-AKI & cancer patient management
Optimal Use of Iodinated Contrast Media In Oncology Patients Focus on CI-AKI & cancer patient management Dr. Saritha Nair Manager-Medical Affairs-India & South Asia GE Healthcare Context Cancer patients
More informationThe Use of Metabolic Resuscitation in Sepsis
The Use of Metabolic Resuscitation in Sepsis Jennifer M. Roth, PharmD, BCPS, BCCCP Critical Care Clinical Specialist - Surgical Trauma ICU Baylor University Medical Center Disclosures No conflicts of interest
More informationCOMPETING INTEREST OF FINANCIAL VALUE
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams
More informationSupplementary Online Content
Supplementary Online Content Downes KJ, Cowden C, Laskin BL, et al. Association of acute kidney injury with concomitant vancomycin and piperacillin/tazobactam treatment among hospitalized children. JAMA
More informationClinical pathological correlations in AKI
Clinical pathological correlations in AKI Dr. Rajasekara chakravarthi Director - Nephrology Star Kidney Center, Star Hospitals Renown clinical services India Introduction AKI is common entity Community
More informationCLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel
CLINICAL USE OF GLYCOPEPTIDES Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel Glycopeptides Natural Vancomycin introduced in 1958 Teicoplanin introduced in Europe
More informationFluid balance in Critical Care
Fluid balance in Critical Care By Dr HP Shum Nephrologist and Critical Care Physician Department of Intensive Care, PYNEH Fluid therapy is a critical aspect of initial acute resuscitation in critically
More informationProfessor and Director. Children s Hospital of Richmond
Evaluation of AKI in term and premature infants Timothy E. Bunchman Professor and Director Pediatric Nephrology & Transplantation Children s Hospital of Richmond Virginia Commonwealth Univ. School of Medicine
More informationPivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More informationCardiorenal syndrome. Sofie Gevaert. Ghent University Hospital, Belgium
Cardiorenal syndrome Sofie Gevaert Ghent University Hospital, Belgium Disclosures Consultancy Astra Zeneca Boegringer MSD Novartis 68 y old man, ADHF ICMP, ejection fraction 35 %: progressive dyspnea,
More informationMedication Dosing in CRRT
Medication Dosing in CRRT Linda Awdishu, PharmD, MAS Associate Clinical Professor of Pharmacy and Medicine Learning Objectives 1. List the pharmacokinetic changes associated with AKI. 2. Determine the
More informationManaging patients with renal disease
Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia Prevalent cases,
More informationCardiovascular Protection and the RAS
Cardiovascular Protection and the RAS Katalin Kauser, MD, PhD, DSc Senior Associate Director, Boehringer Ingelheim Pharmaceutical Inc. Micardis Product Pipeline Scientific Support Ridgefield, CT, USA Cardiovascular
More informationKetorolac Prescribing Practices in an Acute Care Hospital and the Incidence of Acute Renal Failure
Elmer Press Original Article Ketorolac Prescribing Practices in an Acute Care Hospital and the Incidence of Acute Renal Failure Joseph Chan a, b, Anil Bajnath a, Beth Fromkin a, Debbie Haine a, Rute Paixao
More informationReducing risk of CKD progression. Arasu Gopinath, MD
Reducing risk of CKD progression Arasu Gopinath, MD Relative risk of outcomes in CKD Delaying CKD progression BP control and RAAS blockade All adults with UACR < 30 mg/g, goal BP < 140/90 All adults with
More informationQUICK REFERENCE FOR HEALTHCARE PROVIDERS
KEY MESSAGES 1 SCREENING CRITERIA Screen: Patients with DM and/or hypertension at least yearly. Consider screening patients with: Age >65 years old Family history of stage 5 CKD or hereditary kidney disease
More informationManagement of Acute Kidney Injury in the Neonate. Carolyn Abitbol, M.D. University of Miami Miller School of Medicine / Holtz Children s Hospital
Management of Acute Kidney Injury in the Neonate Carolyn Abitbol, M.D. University of Miami Miller School of Medicine / Holtz Children s Hospital Objectives Summarize the dilemmas in diagnosing & recognizing
More informationRenal Disease and PK/PD. Anjay Rastogi MD PhD Division of Nephrology
Renal Disease and PK/PD Anjay Rastogi MD PhD Division of Nephrology Drugs and Kidneys Kidney is one of the major organ of drug elimination from the human body Renal disease and dialysis alters the pharmacokinetics
More informationBiomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland
Biomarkers for optimal management of heart failure Cardiorenal syndrome Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland Presenter Disclosure Information V-P Harjola The following
More informationAcute Kidney Injury. I. David Weiner, M.D. Division of Nephrology, Hypertension and Transplantation University of Florida and NF/SGVHS
Acute Kidney Injury I. David Weiner, M.D. Division of Nephrology, Hypertension and Transplantation University of Florida and NF/SGVHS 374-6102 David.Weiner@medicine.ufl.edu www.renallectures.com Concentration
More informationDEFINITION, CLASSIFICATION AND DIAGNOSIS OF ACUTE KIDNEY INJURY
DEFINITION, CLASSIFICATION AND DIAGNOSIS OF ACUTE KIDNEY INJURY JOSÉ ANTÓNIO LOPES, MD, PhD Faculty of Medicine, University of Lisbon Department of Nephrology and Renal Transplantation Centro Hospitalar
More informationManagement of early chronic kidney disease
Management of early chronic kidney disease GREENLANE SUMMER GP SYMPOSIUM 2018 Jonathan Hsiao Renal and General Physician Introduction A growing public health problem in NZ and throughout the world. Unknown
More informationAcute Kidney Injury Care in the Chronic Unit
Acute Kidney Injury Care in the Chronic Unit BONNIE B GREENSPAN WITH ASSIST FROM: DENISE MURCEK, JINA BOGLE, MARY SCHIRA, OCTOBER 5, 2017 Objectives At the completion of the session, engaged participants
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationAcute Kidney Injury. Amandeep Khurana, MD Southwest Kidney Institute
Acute Kidney Injury Amandeep Khurana, MD Southwest Kidney Institute 66 yr white male w/ DM, HTN, CAD admitted to an OSH w/ E Coli UTI on 7/24/16, developed E Coli bacteremia and Shock (on vaso + levo)
More informationVA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERENCE CARDS Chronic Kidney Disease
VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERECE CARDS Chronic Kidney Disease CKD VA/DoD Clinical Practice Guideline for the Management
More informationCreatinine & egfr A Clinical Perspective. Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC
Creatinine & egfr A Clinical Perspective Suheir Assady MD, PhD Dept. of Nephrology & Hypertension RHCC CLINICAL CONDITIONS WHERE ASSESSMENT OF GFR IS IMPORTANT Stevens et al. J Am Soc Nephrol 20: 2305
More informationCardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology
Cardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology Heart and Kidney The kidney yin dominates water, The heart yang
More informationAcute (Tubulo-) Interstitial Nephritis (TIN)
Acute (Tubulo-) Interstitial Nephritis (TIN) Rodney D Gilbert Case 1 16 year old girl with intractable psychosis Started Clozapine Monitored closely 6 weeks later: AKI Creatinine 200 How would you manage?
More informationInternational Journal of Medical and Health Sciences
International Journal of Medical and Health Sciences Journal Home Page: http://www.ijmhs.net ISSN:2277-4505 Original article Incidences and clinical outcomes of acute kidney injury in PICU: A prospective
More informationAvoiding the triple whammy in primary care: ACE inhibitor/arb + diuretic + NSAID
Adverse drug reactions and interactions Medicines management Nephrology Pain management Avoiding the triple whammy in primary care: ACE inhibitor/arb + diuretic + NSAID Angiotensin converting enzyme (ACE)
More informationProton Pump Inhibitors and Renal Disease/RAAS Blockade Reconsidered
Proton Pump Inhibitors and Renal Disease/RAAS Blockade Reconsidered Mark D. Baldwin D.O. FACOI Chair of Clinical Medicine Pacific Northwest University of Health Sciences Yakima, WA Disclosures None, just
More informationHello, and thank you for joining us for this presentation on novel approaches to understanding risks and treatment of hyperkalemia.
Hello, and thank you for joining us for this presentation on novel approaches to understanding risks and treatment of hyperkalemia. PP-US-DSE-00032. 2015 Relypsa, Inc. All rights reserved. Relypsa and
More informationLithium toxicity. Dr Aude Servais Service de Néphrologie adulte Hôpital Necker, Paris
Lithium toxicity Dr Aude Servais Service de Néphrologie adulte Hôpital Necker, Paris Lithium Use of lithium salts as salt substitutes but recall from the marketplace in 1949 Efficient in the treatment
More informationThe Risk Study. A prospective, multi-centre, evaluation of an AKI risk prediction tool for emergency hospital admissions
The Risk Study A prospective, multi-centre, evaluation of an AKI risk prediction tool for emergency hospital admissions Disclosures Research Funding Commercial Trials Honorarium/Travel Astute Medical SBRI/D4D
More informationAcute Kidney Injury. Arvind Bagga All India Institute of Medical Sciences New Delhi, India
Acute Kidney Injury Arvind Bagga All India Institute of Medical Sciences New Delhi, India What is AKI? Sudden loss of renal function, over hrdays, with derangement(s) in fluid balance, acid base & electrolytes
More informationElevated Serum Creatinine, a simplified approach
Elevated Serum Creatinine, a simplified approach Primary Care Update Creighton University School of Medicine. April 27 th, 2018 Disclosure Slide I have no disclosures and have no conflicts with this presentation.
More informationArasu Gopinath, MD Nephrology Associates of Utah
Arasu Gopinath, MD Nephrology Associates of Utah Topics of interest PPI and CKD Diet soda consumption and risk of Incident ESRD Dietary red meat and kidney toxicity Chronic interstitial nephritis in agricultural
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationAcute Kidney Injury. APSN JSN CME for Nephrology Trainees May Professor Robert Walker
Acute Kidney Injury APSN JSN CME for Nephrology Trainees May 2017 Professor Robert Walker Kidney International (2017) 91, 1033 1046; http://dx.doi.org/10.1016/ j.kint.2016.09.051 Case for discussion 55year
More informationAngiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease
Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) To STOP OR Not in Advanced Renal Disease Investigator Meeting 12 th September 2017 - Sheffield Prof Sunil Bhandari Consultant
More informationDialyzing challenging patients: Patients with hepato-renal conditions
Dialyzing challenging patients: Patients with hepato-renal conditions Nidyanandh Vadivel MD Medical Director for Living kidney Donor and Pancreas Transplant Programs Swedish Organ Transplant, Seattle Acute
More informationManagement of the Frail Older Patients: What Are the Outcomes
Management of the Frail Older Patients: What Are the Outcomes Professor Edwina Brown Imperial College Renal and Transplant Centre Hammersmith Hospital, London Increasing prevalence of old old on RRT RRT
More informationPredicting and changing the future for people with CKD
Predicting and changing the future for people with CKD I. David Weiner, M.D. Co-holder, C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationStressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU
Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds November 8, 2016 2016 MFMER slide-1 Objectives Identify the significance
More informationCKD IN THE CLINIC. Session Content. Recommendations for commonly used medications in CKD. CKD screening and referral
CKD IN THE CLINIC Family Physician Refresher Course Lisa M. Antes, MD April 19, 2017 No disclosures Session Content 1. 2. Recommendations for commonly used medications in CKD Basic principles /patient
More information